| Drug General Information |
| Drug ID |
D00FUO
|
| Former ID |
DNC012292
|
| Drug Name |
NAFOXIDINE
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C29H31NO2
|
| InChI |
InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
|
| InChIKey |
JEYWNNAZDLFBFF-UHFFFAOYSA-N
|
| CAS Number |
CAS 1845-11-0
|
| PubChem Compound ID |
|
| PubChem Substance ID |
794529, 5096570, 7847022, 8152730, 14905117, 29223513, 48110654, 48421892, 50038542, 53788181, 57322262, 77903400, 93165515, 103195570, 103960656, 104306343, 124899377, 125669770, 126665811, 128265252, 128265253, 134349497, 134980548, 137009443, 142396265, 178101080, 179150105, 198983433, 223442309, 223662464, 223860366, 226517813, 250095402
|
| Target and Pathway |
| Target(s) |
Estrogen receptor beta |
Target Info |
Inhibitor |
[2]
|
|---|
| Estrogen receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
Reactome
|
Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Integrated Pancreatic Cancer Pathway
|
|
Nuclear ReceptorsWP712:Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4263). |
|---|
| REF 2 | J Med Chem. 1998 Jul 30;41(16):2928-31.Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. |
|---|
